Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 5/20 | 0.59 |
| ▸ | ABL1 | P00519 | 5/20 | 0.59 |
| ▸ | EGFR | P00533 | 5/20 | 0.59 |
| ▸ | HCK | P08631 | 5/20 | 0.59 |
| ▸ | SRC | P12931 | 5/20 | 0.59 |
| ▸ | KDR | P35968 | 5/20 | 0.59 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.59 |
| ▸ | MTOR | P42345 | 5/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.59 |
| ▸ | EPHB4 | P54760 | 5/20 | 0.59 |
| ▸ | PRKDC | P78527 | 5/20 | 0.59 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | USP7 | Q93009 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | EIF2AK3 | Q9NZJ5 | 8/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12162 | 0.79 | PIK3CD (0.74) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL13314352 | 0.78 | SRC (0.53) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL18044717 | 0.76 | KDR (0.59) | ABL1EGFRSRCKDRFLT3 | |
| SCHEMBL20351544 | 0.75 | EIF2AK3 (0.49) | PIK3CDSRCKDRPIK3CAPIK3CB | |
| SCHEMBL20351725 | 0.75 | MET (0.48) | ABL1EGFRSRCKDREIF2AK3 | |
| SCHEMBL20351597 | 0.74 | EIF2AK3 (0.50) | ABL1EGFRSRCKDREIF2AK3 | |
| SCHEMBL20351783 | 0.74 | RIPK2 (0.61) | SRCEIF2AK3FLT3 | |
| SCHEMBL868609 | 0.74 | EIF2AK3 (0.52) | EIF2AK3RIPK1 | |
| SCHEMBL23917434 | 0.73 | SRC (0.61) | PIK3CDABL1EGFRHCKSRC | |
| SCHEMBL13020096 | 0.73 | SRC (0.69) | ABL1EGFRHCKSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108631-B | 6-amino-7-bicyclic-7-deaza-purine derivatives as protein kinase inhibitors | 内尔维阿诺医学科学有限公司 | 2020-06-16 | — | — | CN | disclosed |
| US-10221181-B2 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-03-05 | — | — | US | disclosed |
| US-10221181-B2 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-03-05 | — | — | US | disclosed |
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEICAL SCIENCES S.r.l. (IT) | 2017-11-16 | — | — | US | disclosed |
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEICAL SCIENCES S.r.l. (IT) | 2017-11-16 | — | — | US | disclosed |
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEICAL SCIENCES S.r.l. (IT) | 2017-11-16 | — | — | US | disclosed |
| EP-3218378-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016075224-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016075224-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327506-A1 | 6-AMINO-7-BICYCLO-7-DEAZA-PURINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | DCK, RET, ADK | PIK3CD 226/4885ABL1 68/4885EGFR 806/4885 |
| US-10221181-B2 | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors | DCK, RET, PRKCA | PIK3CD 247/4885ABL1 78/4885EGFR 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.